This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Levicure LLC


LeviCure Ltd. is an Israeli start-up, part of Startup Health T1D Moonshot program that aims to provide an effective oral treatment for type 1 diabetes mellitus (T1DM). Our IP is secured by an extensive patent portfolio for an orally administered therapy that consists of a combination of three FDA-approved molecules. Our innovative therapy has been shown to facilitate remission of T1DM through restoring own insulin production, stabilizing blood glucose levels and significantly decreasing exogenous insulin demands, in many cases achieving complete insulin withdrawal in humans. With oral triple-therapy it is possible to provide patients suffering from T1DM a safe, affordable and effective, non-invasive, orally administered therapy that will facilitate remission, minimize complications and immeasurably improve their quality of life. - NOD mice data in Frontiers Endocrinology: - Human data results in Frontiers Endocrinology: